Funding Round
Axoft Raises $55M Series A for Implantable BCI
Cure Medtech Funding Tracker4/29/2026·04/29/26🌐 USA
Summary
Axoft raised an oversubscribed $55M Series A, bringing total funding to over $60M. The Cambridge-based company will use capital to expand clinical trials and advance U.S. regulatory approval of implantable BCIs.
Why it matters
Axoft's $55M Series A validates investor appetite for soft, bio-inspired neural interfaces that reduce the immune rejection seen in rigid BCI implants. The round accelerates clinical trials and positions the company among a growing cohort of next-generation implantable BCI developers competing with Neuralink and Synchron.
#BCI#Electrode Technology#Industry#Neural Interfaces#Venture Capital
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in